Licensing status

Publication and contact information


Cerebrospinal fluid (CSF) levels of soluble CD19 to detect CNS disease in patients with lymphoma

Human sample studies suggest measuring soluble CD19 in CSF could be used to detect CNS disease in lymphoma patients and to aid prognosis and guide treatment. In CSF samples from 91 patients with diffuse large B cell lymphoma (DLBCL) and 22 with Burkitt lymphoma, high levels of soluble CD19 were found in patients with overt CNS disease that was either detectable by the presence of lymphoma cells in flow cytometry analysis or by suspicious neurological symptoms. In the samples, high soluble CD19 levels were associated with shorter event-free and overall survival. Next steps include improving the accessibility of the method.

SciBX 7(11); doi:10.1038/scibx.2014.329
Published online March 20, 2014

Patent application filed; available for licensing

Muñiz, C. et al. Blood; published online Feb. 5, 2014;
Contact: Alberto Orfao, Institute of Biomedical Investigation of Salamanca and University of Salamanca, Salamanca, Spain